NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-08-14 15:55இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Vaishali Pharma's board approved the unaudited financial results for the first quarter ended June 30, 2026, during its meeting on August 14, 2026. The company also finalized the 19th Annual General Meeting (AGM) for September 24, 2026, and set the book closure period from September 18 to September 24. This follows a fiscal year (FY26) where the company reported a revenue of Rs 85.03 Cr and a net profit of Rs 2.92 Cr. Investors are monitoring the company's strategic shift from low-margin API trading to high-margin formulations to improve its 3.23% operating margin.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board has officially approved the first-quarter performance figures for FY27 and established the timeline for the annual shareholder meeting and book closure.
ஏன் இது முக்கியம்This filing initiates the formal reporting cycle for the new fiscal year and provides the necessary schedule for shareholders to participate in the upcoming AGM.
📅 குறுகிய காலம்The stock may see minor activity as investors digest the Q1 FY27 earnings performance relative to previous quarters.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to successfully transition from a thin-margin API trader to a higher-margin formulation and veterinary product player.
⚠ அபாய எச்சரிக்கைகள்
Thin operating margins (3.23% in FY26)
High revenue dependency (60%) on volatile API trading prices
Relatively low promoter holding at 30.54%
👀 கவனிக்க வேண்டியவை
Investors should examine the Q1 FY27 results to verify if the operating margin is expanding beyond the FY26 level of 3.23% as the company pivots toward branded formulations.
45.37 Lakh shares allotted to Kesar Pharma for 26.95% stake acquisition
Vaishali Pharma has completed the allotment of 45,37,865 equity shares at an issue price of Rs 20 per share to Kesar Pharma Limited (KPL). This is a non-cash transaction valued at Rs 9.08 Cr, executed as a share swap to acquire a 26.95% stake in KPL. The allotment increases Vaishali's total paid-up equity shares to 13.50 Cr, with KPL now holding a 3.36% stake in the company. This move aligns with the company's strategy to expand its pharmaceutical footprint through strategic investments.
உச்சம் நம்பிக்கை
என்ன மாறியதுVaishali Pharma has issued new equity shares to Kesar Pharma Limited as consideration for acquiring a 26.95% stake in the latter.
ஏன் இது முக்கியம்This strategic investment allows Vaishali to expand its pharmaceutical interests without cash outflow, though it results in a 3.36% equity dilution for existing shareholders.
Total Allotment Value: Rs 9.08 கோடிStake Acquired in KPL: 26.95%Issue Price per Share: Rs 20Transaction vs Net Worth: 13.16%Post-Issue Total Shares: 13,49,99,995
📅 குறுகிய காலம்The market is likely to view the completion of this long-pending acquisition (initiated in Feb 2026) as a positive step toward inorganic growth.
📈 நீண்ட காலம்The acquisition of a significant minority stake in KPL could provide synergies in the formulation and API segments, supporting the company's margin expansion goals.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of 3.36%
Valuation risk of the acquired stake in a non-listed entity
Integration and synergy realization risks
👀 கவனிக்க வேண்டியவை
Investors should monitor the financial performance of Kesar Pharma Limited as an associate company and observe how this acquisition aids Vaishali's target of reaching Rs 500 Cr revenue in 5 years.
Vaishali Pharma to Receive Rs 2.15 Lakh Cash from KPL to Align Share Swap Valuation
Vaishali Pharma Limited is addressing a valuation discrepancy regarding its preferential issue of 61,23,000 equity shares to Kesar Pharma Limited (KPL). The company originally valued KPL shares at Rs 56.89 for the swap, but the registered valuer's report cited Rs 56.79, a difference of Rs 0.10 per share. To satisfy NSE's observations for in-principle approval, KPL will pay the aggregate differential of Rs 2,15,258 in cash to Vaishali Pharma. This adjustment ensures the transaction aligns perfectly with the valuation report and regulatory requirements.
முக்கிய அம்சங்கள்
Preferential issuance of up to 61,23,000 equity shares to Kesar Pharma Limited (KPL) via share swap.Acquisition involves 21,52,575 equity shares of KPL.Valuation discrepancy of Rs 0.10 per share identified between company calculation and valuer report.KPL to pay Rs 2,15,258 in cash to bridge the valuation gap for regulatory compliance.Adjustment made specifically to address National Stock Exchange (NSE) observations for in-principle approval.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine regulatory correction that clears the path for the completion of the preferential issue. Monitor for the final in-principle approval from the NSE to confirm the transaction's progress.
Vaishali Pharma Proposes Re-appointment of MD and WTD, and CFO Remuneration Hike
Vaishali Pharma Limited has issued a postal ballot notice seeking shareholder approval for the re-appointment of its core leadership team for five-year terms. This includes Managing Director Atul Arvind Vasani and Whole-Time Director Jagruti Vasani, both for terms ending in May 2031. Additionally, the company is proposing a second five-year term for Independent Director Pratik Vikram Jakhelia and an increase in remuneration for CFO Dewansh Ajay Vasani. The voting process will be conducted electronically between June 4 and July 3, 2026.
முக்கிய அம்சங்கள்
Proposed 5-year re-appointment of Managing Director Atul Arvind Vasani effective from May 23, 2026.Proposed 5-year re-appointment of Whole-Time Director Jagruti Vasani effective from May 23, 2026.Resolution to increase the remuneration payable to Dewansh Ajay Vasani, Director and CFO.Re-appointment of Pratik Vikram Jakhelia as Independent Director for a second term until September 30, 2031.E-voting period scheduled from June 4, 2026, to July 3, 2026, with results by July 7, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to ensure leadership continuity and review the explanatory statement to assess if the CFO's remuneration hike is justified by company performance.
Vaishali Pharma Approves Audited Q4 and FY26 Financial Results
The Board of Directors of Vaishali Pharma Limited met on May 30, 2026, to approve the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The meeting was held late in the evening, concluding at 10:50 P.M. This announcement confirms the completion of the annual audit process in compliance with SEBI regulations. While specific financial figures were not detailed in the cover letter, the approval marks the formal release of the company's performance data for the 2025-26 fiscal year.
முக்கிய அம்சங்கள்
Board approved Audited Standalone and Consolidated Financial Results for the year ended March 31, 2026.The meeting was conducted on May 30, 2026, starting at 10:00 P.M. and ending at 10:50 P.M.The submission includes the Audit Report for both the fourth quarter and the full financial year.Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial tables in the attached Annexure I to assess revenue growth and margin stability. Compare the full-year FY26 performance against FY25 to determine the company's growth trajectory.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Vaishali Pharma Re-appoints MD Atul Vasani and Two Directors for 5-Year Terms
Vaishali Pharma Limited has announced the re-appointment of its core leadership team for five-year terms during its board meeting on May 23, 2026. Mr. Atul Arvind Vasani, the promoter and chairman with over 30 years of industry experience, has been re-appointed as Managing Director until May 2031. Mrs. Jagruti Vasani continues as Whole-Time Director, while Mr. Pratik Vikram Jakhelia has been re-appointed as an Independent Director for a second term. These leadership extensions, subject to shareholder approval, ensure management continuity and stability for the company's long-term operations.
முக்கிய அம்சங்கள்
Mr. Atul Arvind Vasani re-appointed as Managing Director for a 5-year term ending May 22, 2031Mrs. Jagruti Vasani re-appointed as Whole-Time Director for 5 years, bringing 15+ years of experienceMr. Pratik Vikram Jakhelia re-appointed as Independent Director for a 2nd term of 5 years starting Sept 2026The leadership team includes the promoter who has been in the pharmaceutical industry since 1987All re-appointments are subject to the final approval of the company's members
👀 கவனிக்க வேண்டியவை
This announcement confirms management continuity, which is a positive sign for long-term stability. Investors should monitor the company's performance under this established leadership.
Vaishali Pharma Shareholders Approve Preferential Issue of Equity Shares
Vaishali Pharma Limited has received shareholder approval through a postal ballot for the issuance and allotment of equity shares on a preferential basis. The special resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor by participating public shareholders. Promoters and the promoter group abstained from voting as they were interested parties in the resolution. This approval clears the path for the company to raise capital, which is typically used for expansion or strengthening the balance sheet.
முக்கிய அம்சங்கள்
Special Resolution for issuing equity shares on a preferential basis was approved by shareholders.The resolution received 99.9909% votes in favor from the public non-institutional category.A total of 25,415,321 votes were polled during the postal ballot process.Promoters and promoter group members abstained from voting due to their interest in the resolution.The record date for determining eligibility for the postal ballot was February 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor upcoming disclosures regarding the specific allotment price and the list of allottees to evaluate the impact of equity dilution. The successful approval indicates strong shareholder support for the company's fundraising and growth plans.
Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share
Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.
முக்கிய அம்சங்கள்
Proposed acquisition of a 51.02% majority stake in Kesar Pharma LimitedPreferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02Relevant date for the transaction pricing is February 13, 2026E-voting facility for shareholders is open until 05:00 PM on March 15, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.
Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma
Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.
முக்கிய அம்சங்கள்
Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per shareTotal consideration of Rs. 12.25 crores to be settled via share swap (non-cash)Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stakeRelevant date for floor price determination fixed as February 13, 2026E-voting results to be announced on or before March 17, 2026
👀 கவனிக்க வேண்டியவை
Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.
Vaishali Pharma has approved the issuance of 61.23 lakh equity shares at Rs 20 each via a preferential allotment. This is a non-cash transaction involving a share swap to acquire 21.52 lakh shares of its associate company, Kesar Pharma Limited, at Rs 56.89 per share. The total value of the issuance is approximately Rs 12.25 Crores, resulting in Kesar Pharma holding a 4.48% stake in the company. Additionally, the board has cleared the unaudited financial results for the quarter and nine months ended December 31, 2025.
முக்கிய அம்சங்கள்
Issuance of 61,23,000 equity shares at a price of Rs 20 per shareTotal deal value of Rs 12.246 Crores via share swap for Kesar Pharma stakeAcquisition of 21,52,575 shares of Kesar Pharma Limited at Rs 56.89 per sharePost-allotment, Kesar Pharma Limited will own 4.48% of Vaishali PharmaBoard approved Q3 FY26 results and initiated a postal ballot for shareholder approval
👀 கவனிக்க வேண்டியவை
Investors should evaluate the valuation of Kesar Pharma and the impact of the 4.48% equity dilution on earnings per share. Watch for the detailed Q3 financial performance to assess the company's growth trajectory.
Vaishali Pharma to Issue 61.23 Lakh Shares via Swap for Kesar Pharma Stake
Vaishali Pharma has approved a preferential allotment of 61.23 lakh equity shares at an issue price of ₹20 per share, totaling approximately ₹12.25 crores. This is a non-cash transaction executed via a share swap to subscribe to 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. Post-allotment, Kesar Pharma will hold a 4.48% stake in Vaishali Pharma. The board also approved the unaudited financial results for the quarter ended December 31, 2025.
முக்கிய அம்சங்கள்
Preferential issue of 61,23,000 equity shares at ₹20 each (including ₹18 premium).Total transaction value for the share swap is ₹12,24,60,000.Acquisition of 21,52,575 shares of associate company Kesar Pharma Limited at ₹56.89 per share.Post-issue, Kesar Pharma Limited will hold a 4.48% equity stake in Vaishali Pharma.Board approved Q3 FY26 financial results and initiated a Postal Ballot for shareholder approval.
👀 கவனிக்க வேண்டியவை
Investors should monitor the strategic benefits of increasing the stake in Kesar Pharma and review the Q3 financial results for operational performance. The share swap indicates a consolidation of interests with its associate company.
Vaishali Pharma: 2,32,70,000 Equity Shares Listed on NSE
Vaishali Pharma Limited received approval from NSE for trading of 2,32,70,000 equity shares of ₹2 each. These shares, bearing distinctive numbers from 107192131 to 130462130, were issued to Promoters and Non-Promoters on a preferential basis following the conversion of warrants. The equity shares were listed and admitted to dealings on the Exchange effective December 09, 2025. Investors should note the lock-in periods for specific share ranges as detailed in Annexure I.
முக்கிய அம்சங்கள்
2,32,70,000 equity shares of ₹2 each listed on NSEShares issued to Promoters and Non-Promoters on preferential basisDistinctive numbers range from 107192131 to 130462130Trading commenced on December 09, 2025Lock-in periods extend up to June 30, 2027 for certain shares
👀 கவனிக்க வேண்டியவை
Investors should review the lock-in details in Annexure I to understand any restrictions on trading these newly listed shares. Monitor the trading activity of these shares for any potential impact on the stock price.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
